Maravai LifeSciences Holdings (MRVI) Stock Overview
A life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for MRVI from our risk checks.
MRVI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Flanders Facilities And New Acquisitions Will Create Future Opportunity
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.28 |
| 52 Week High | US$10.03 |
| 52 Week Low | US$1.67 |
| Beta | 0.25 |
| 1 Month Change | 7.55% |
| 3 Month Change | -5.79% |
| 1 Year Change | -71.07% |
| 3 Year Change | -91.50% |
| 5 Year Change | n/a |
| Change since IPO | -92.36% |
Recent News & Updates
Recent updates
Flanders Facilities And New Acquisitions Will Create Future Opportunity
Strategic partnerships and new product launches drive diversification and growth across the business.Positive Sentiment Still Eludes Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Following 25% Share Price Slump
Feb 08
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 43%?
Jan 15Maravai LifeSciences: Still Struggling To Find Its Footing
Nov 25Slammed 37% Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Screens Well Here But There Might Be A Catch
Nov 11Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Oct 15Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Jul 18Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Jul 12RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Shareholder Returns
| MRVI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.2% | 4.5% | 1.2% |
| 1Y | -71.1% | -24.2% | 11.2% |
Return vs Industry: MRVI underperformed the US Life Sciences industry which returned -23.8% over the past year.
Return vs Market: MRVI underperformed the US Market which returned 12.8% over the past year.
Price Volatility
| MRVI volatility | |
|---|---|
| MRVI Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 11.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: MRVI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRVI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 580 | Bernd Brust | www.maravai.com |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MRVI fundamental statistics | |
|---|---|
| Market cap | US$550.06m |
| Earnings (TTM) | -US$162.71m |
| Revenue (TTM) | US$241.86m |
Is MRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVI income statement (TTM) | |
|---|---|
| Revenue | US$241.86m |
| Cost of Revenue | US$151.67m |
| Gross Profit | US$90.19m |
| Other Expenses | US$252.90m |
| Earnings | -US$162.71m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 37.29% |
| Net Profit Margin | -67.28% |
| Debt/Equity Ratio | 55.6% |
How did MRVI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/11 04:18 |
| End of Day Share Price | 2025/06/11 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Maravai LifeSciences Holdings, Inc. is covered by 15 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Erin Wilson Wright | Credit Suisse |